Introduction

The short bowel syndrome (SBS) is a pathological condition caused by extensive intestinal surgical resections or congenital diseases leading to a severe reduction of the absorptive intestinal surface.1 SBS is the main cause of chronic intestinal failure (IF) that occurs when gut function declines below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, requiring intravenous supplementation for the maintenance of health and/or growth.1

The traditional management of SBS involves the use of specialized diets, anti-diarrhoea/antisecretory drugs and parenteral nutrition (PN) or intravenous fluids (IVF) to meet nutritional requirements, while intestinal transplantation is applied only in patients that cannot be managed with traditional approaches.2 New pharmacological therapies for SBS have been aimed at improving intestinal adaptation to increase the bowel absorption capacity and reduce the patient’s dependence on PN. However, somatostatin demonstrated only temporary beneficial effects in all randomized clinical trials, because the increased body weight and intestinal absorption disappeared after the therapy was discontinued.3–4 Teduglutide, a recombinant glucagon-like peptide 2, was able to increase both the height of intestinal villi and the depth of crypts,2–4 inducing a reduction of PN volume (in 79% of the cases) or PN discontinuation (in 21% of the cases).5 However, the elevated cost of this drug and its unavailability in many European countries are limits to its use.

A different therapeutic approach to the treatment of SBS was attempted by Lange et al6 through the use of modified cereals (SPC-Flakes, Medifood, Switzerland) that stimulate the endogenous production of the antisecretory factor (AF). This hormone controls water and electrolyte transport through cellular membranes by inhibiting GABAergic effects on intestinal epithelium.7,8 Davidson and Hickey9 have also suggested a possible role of AF as an anti-inflammatory agent. Most of the AF in plasma is present in inactive form and is activated after exposure to intestinal bacteria or after the intake of foods that create a hypertonic environment in the intestine.10 Clinical studies in patients suffering from inflammatory bowel diseases and neuroendocrine tumours treated with SPC-Flakes have yielded encouraging results.11–14 On the contrary, in patients with SBS, the number of bowel movements remained unmodified during and after treatment with SPC-Flakes (54 g/day) for 2 weeks.6 However, the latter study suffered from some limitations: (1) only the number of bowel movements was evaluated and not faecal volume; (2) the SPC-Flakes dosage was not adjusted for body weight as recommended by the producer; (3) the period of administration of SPC-Flakes was too short (the
endogenous AF is activated between 14 and 28 days after administration of SPC-Flakes); (4) the administration of the exogenous AF (Salovum, PIAM Farmaceutici SPA, Genova, Italy) was not tested.

In our study, we evaluated, for the first time, the effect of Salovum alone followed by a combination of Salovum with SPC-Flakes and then SPC-Flakes alone, administered for a total duration of 37 days in patients with SBS and chronic IF undergoing PN. To this purpose, intestinal absorption, hydration, nutrition, and inflammation were assessed to evaluate the possibility of reducing the PN/IVF support.

Methods
We enrolled 7 patients affected by SBS with chronic IF requiring PN support. These patients were followed as outpatients by the nutritional team of the Gastroenterology Unit. We excluded patients with acute IF or chronic IF due to causes other than SBS, and patients with faecal volume/stoma effluent < 300 mL/day. Informed consent was obtained from each patient, and the study was conducted in agreement with the ethical guidelines of the Declaration of Helsinki and received the approval by the local Ethics Committee.

Before enrolment, all patients were invited to discontinue their chronic anti-diarrhoea therapies. At baseline (T₀), in addition to demographic and clinical data, the following parameters were recorded: faecal volume/stoma effluent, urinary volume, PN volumes, amount of liquid taken orally, weight, height, lean mass (FFM), total body water (TBW), extracellular water (ECW), dietary intake, and blood tests.

According to the clinical classification of chronic IF proposed by Pironi et al, taking into account the calories and liquids infused, our patients were categorized into subtypes.

The daily faecal volume/stoma effluent, urinary volume, and oral liquids intake were obtained by calculating the average of 3 consecutive days. Weight and height were measured using a digital scale with altimeter (Soehnle 7831, Soehnle srl Italy, Como, CO, Italy), and the body mass index (BMI) was expressed as kg/m².

FFM, TBW, and ECW were measured by bioelectrical impedance analysis (BIA 101, Akern srl, Pontassieve, FI, Italy) and expressed as percentage of body weight. TBW values were considered normal at 50% to 60% in men and 55% to 65% in women, and ECW values at 43%.

To evaluate the daily dietary intake, an experienced dietitian collected a dietary history and, with the help of software (Winfood3, Medimatica Srl, Colonnella, TE, Italy), calculated the average calorie intake. C-reactive protein (CRP) was measured to assess the patients’ inflammation status, while albumin, transferrin, total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides were measured to assess nutritional status.

Patients were invited to take SPC-Flakes without food or beverages, dividing the total daily amount in 3 administrations. Salovum was taken with bread in 3 doses per day. Study design was reported in Figure 1.

Statistical analysis was performed using Wilcoxon exact test for paired data. Statistical significance was set at \( P < 0.05 \) and was performed using SPSS version 21.0 software.

Results
Among the 7 patients enrolled in the study, 2 patients discontinued treatment within the first week due to side effects (abdominal pain, increased stoma effluent and decreased diuresis). In addition, 1 patient was excluded from the analysis because, after the end of the study, he was affected by pancreatic cancer.

Among the remaining 4 patients, 1 discontinued the treatment before T₃ because he developed an acute infectious gastroenteritis. None of these 4 patients suffered treatment-related side effects. Demographic and clinical characteristics of these patients are shown in Table 1.

All patients were adults with a good nutritional status (stable body weight and normal BMI). According to the clinical classification of chronic IF proposed by Pironi et al, 2 patients were classified as B2 subtype, 1 patient as C2 subtype, and 1 patient as C3 subtype.
Table 2 shows the water balance comparing the faecal volume/stoma effluent, the urinary volume, and the oral liquid intake volume at T₁, T₂, T₃, and Ts with baseline (T₀). Input fluids (PN and oral liquid intake) remained constant throughout the treatment. Statistical analysis showed no statistically significant differences in faecal volume/stoma effluent at T₁ (after therapy with Salovum), at T₂ (after combination therapy with Salovum plus SPC-Flakes), at T₃ (after therapy with only SPC-Flakes), and at Ts (30 days after the end of treatment) compared with T₀. However, a trend towards increased of faecal volume/stoma effluent was observed at T₃. No statistically significant change in diuresis was noted.

At the end of treatment, there were no changes of either weight or dietary intake, or FFM (Table 3).

Table 1. Demographic and clinical characteristics of patients.

|                     | No. of patients | M/F | Age (mean ± SD) | BMI (mean ± SD) | No. of patients with/without enterostomy | Diagnosis                    | PN volume (mL) (mean ± SD) | Calorie intake by PN (kcal) (mean ± SD) |
|---------------------|-----------------|-----|-----------------|-----------------|-----------------------------------------|-----------------------------|--------------------------|---------------------------------------|
| N. of patients      | 4               | 3/1 | 66.5 ± 9.9      | 24.2 ± 2.3      | 2/2                                     | Crohn disease 1             | 1683.2 ± 558.8           | 731.2 ± 197.2              |

Abbreviations: BMI, body mass index; PN, parenteral nutrition.

Table 2. Water balance during and after treatment.

|                      | T₀ VS T₁  | P₀      | T₀ VS T₂  | P₀      | T₀ VS T₃  | P₀      | T₀ VS TS | P₀      |
|----------------------|-----------|---------|-----------|---------|-----------|---------|----------|---------|
| N. of pts.           | 4 vs 4    | 4 vs 4  | 3 vs 3    | 3 vs 3  |
| Faecal or stoma      | 928.0 ± 509.6 vs 1021.5 ± 606.0 | 0.62 | 928.0 ± 509.6 vs 977.7 ± 557.9 | 0.62 | 726.3 ± 381.6 vs 907.3 ± 382.9 | 0.25 | 726.3 ± 381.6 vs 1020.0 ± 651.0 | 0.50 |
| effluent volume       |           |         |           |         |           |         |          |         |
| Urinary volume        | 1735.0 ± 621.8 vs 1832.0 ± 647.6 | 0.25 | 1735.0 ± 621.8 vs 1711.0 ± 670.6 | 0.87 | 1952.3 ± 544.7 vs 1772.3 ± 909.9 | 0.75 | 1952.3 ± 544.7 vs 1879.0 ± 740.6 | 0.75 |
| Oral liquids taken    | 833.2 ± 514.6 vs 879.2 ± 668.7 | 0.87 | 833.2 ± 514.6 vs 966.7 ± 803.0 | 1     | 1016.6 ± 442.0 vs 1141.6 ± 764.7 | 1     | 1016.6 ± 442.0 vs 1091.6 ± 787.5 | 1     |

All volumes reported are expressed as ml. Values are expressed as mean ± SD.
*By Wilcoxon exact test.

Biochemistry parameters of nutritional status and inflammation state also remained constant (Supplementary Table I).

Discussion

The management of the SBS is challenging, because even the new therapies are not completely effective, are expensive, are associated to significant side effects, and are not always able to allow a complete discontinuation of PN. Therefore, it is important to find new strategies that can overcome these limitations. Our study was conducted in an attempt to improve the intestinal absorption in patients with SBS, using foods for special medical purposes already available on the market in America and Europe, which are inexpensive and safe.

In the past, Lange et al⁶ did not achieve good results with SPC-Flakes when administered in patients with SBS. However, this failure could be explained by the fact that the endogenous AF production is reduced in relation to the intestinal length.⁶ Moreover, the dosage and duration of therapy were not adequate. Our study endeavoured to overcome these limitations by proposing treatment with Salovum, which does not require intestinal integrity for its activation, followed by an adequate dosage and duration of SPC-Flakes.

Our study showed that Salovum does not improve the intestinal absorption in patients with SBS either when used alone or in combination with SPC-Flakes. Indeed, monotherapy with SPC-Flakes leads a trend towards increased intestinal secretions, probably as a result of the hypertonic environment, determining a further passage of liquids in the impaired intestine that is unable to activate sufficient amounts of endogenous AF. This increase did not reach statistical significance for the low number of patients. However, the increase of the intestinal secretions did not induce dehydration because the TBW remained stable. The nutritional status and inflammation state were not affected by the treatment.

The high proportion of patients suffering side effects and the poor efficacy of the therapy caused us to suspend the study and any further enrolment of patients.
In conclusion, the exogenous administration of AF or stimulation of endogenous AF does not seem to offer an effective antisecretory and anti-inflammatory therapy in patients with SBS.

Author Contributions
MTV and MB equally contributed to the conception and design of the research; MTV contributed to the acquisition and analysis of the data; MTV and MB contributed to the interpretation of the data; MTV, ADL, and MB drafted the manuscript. All authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.

Supplemental material
Supplemental material for this article is available online.

ORCID iD
Michele Barone [https://orcid.org/0000-0001-8284-5127]